<SEC-DOCUMENT>0000914475-23-000065.txt : 20231005
<SEC-HEADER>0000914475-23-000065.hdr.sgml : 20231005
<ACCEPTANCE-DATETIME>20231005070238
ACCESSION NUMBER:		0000914475-23-000065
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231005
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231005
DATE AS OF CHANGE:		20231005

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		231309798

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-20231005.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:8a23c82e-d2e5-466b-b77d-87fd67dcc786,g:f905e71f-70d7-43cf-b9d1-06aef8084df6,d:e28489708818481c8583d42257c3870a--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20231005</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0000914475</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20231005.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-05</xbrli:startDate><xbrli:endDate>2023-10-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie28489708818481c8583d42257c3870a_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 5, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><img src="nbix-20231005_g1.jpg" alt="nbix.jpg" style="height:77px;margin-bottom:5pt;vertical-align:text-bottom;width:420px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-22705</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">33-0525145</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Commission</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">12780 El Camino Real,</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">92130</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">617-7600</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Title of each class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></td></tr><tr style="height:0pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie28489708818481c8583d42257c3870a_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 5, 2023, Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;) issued a press release announcing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">top-line results from the Company&#8217;s Phase 3 CAHtalyst&#8482; Pediatric Study. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s press release, issued on October 5, 2023, is attached hereto as Exhibit 99.1.</span></div><div id="ie28489708818481c8583d42257c3870a_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix2023105-exhibit991.htm">Press Release issued by Neurocrine Biosciences, Inc. dated October 5, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie28489708818481c8583d42257c3870a_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: October 5, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Darin M. Lippoldt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix2023105-exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i75b26655fe7f480f99de6c319a04515d_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:36pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:0.08pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints</font></div><div><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.8pt">CAHtalyst</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and Adolescents with Congenital Adrenal Hyperplasia</font></div><div style="margin-top:3pt;padding-left:36pt;padding-right:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.8pt">Key Secondary Endpoint Demonstrated a Statistically Significant Decrease from Baseline in Daily Glucocorticoid Dose while Maintaining Androgen Control </font></div><div style="margin-top:3pt;padding-left:36pt;padding-right:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.8pt">Crinecerfont Was Generally Well-Tolerated </font></div><div style="padding-left:36pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:4.8pt">Company to Host Conference Call and Webcast Today at 8&#58;00 a.m. ET with Management and Dr. Richard Auchus, Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SAN DIEGO, October 5, 2023 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc. (Nasdaq&#58; NBIX) today announced positive top-line data from the Phase 3 CAHtalyst&#8482; Pediatric Study evaluating </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the efficacy, safety, and tolerability of crinecerfont </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crinecerfont is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an oral, selective corticotropin-releasing factor type 1 receptor antagonist </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being investigated to help </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce and control excess adrenal androgens through a steroid-independent mechanism.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The outstanding safety and efficacy results reported today for the CAHtalyst Pediatric study and last month for the CAHtalyst Adult study demonstrate the potential benefit of crinecerfont across all groups studied, including children, adolescents and adults,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer, Neurocrine Biosciences, Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;As a pediatric endocrinologist, I&#8217;m highly encouraged by the results from the CAHtalyst Pediatric study and the potential of crinecerfont to shift the treatment paradigm for a disorder that has seen little innovation in many decades,&#8221; said Kyriakie Sarafoglou, M.D., Professor, Department of Pediatrics and Department of Experimental and Clinical Pharmacology, Divisions of Endocrinology and Genetics &#38; Metabolism, University of Minnesota.  &#8220;The data suggest that crinecerfont might enable us to smooth out the numerous adjustments we have to make in glucocorticoid doses to manage high androgen levels as children grow, potentially improving clinical outcomes related to androgen excess as well as chronic supraphysiologic glucocorticoid dosing.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 3 Pediatric study met its primary endpoint, demonstrating that treatment with crinecerfont resulted in a statistically significant decrease in serum androstenedione from baseline at Week 4 versus placebo following a glucocorticoid (GC) stable period (p &#61; 0.0002). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly and consistent with the results from the Phase 3 CAHtalyst Adult study, crinecerfont treatment led to a statistically significant percent reduction from baseline in daily GC dose while maintaining androgen control at Week 28 versus placebo (p &#60; 0.0001). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 30% of participants receiving crinecerfont achieved a reduction to a physiologic GC dose while maintaining androgen control compared to 0% of participants receiving placebo. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study also met the other key secondary endpoint demonstrating a statistically significant decrease in serum 17-hydroxyprogesterone from baseline at Week 4 versus placebo (p &#60; 0.0001).</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Common Endpoints in CAHtalyst&#8482; Phase 3 Studies</font></td><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">P-value</font></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Adult<br>n &#61; 182</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Pediatric<br>n &#61; 103</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Serum Androstenedione</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> &#8211; Change from baseline at Week 4</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#60;0.0001</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.0002</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">GC Total Daily Dose &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Percent change from baseline at Week 24 (Adult) &#47; Week 28 (Peds), while maintaining androstenedione control</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#60;0.0001</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#60;0.0001</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Achieving Reduction to Physiologic GC Dose &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">At Week 24 (Adult) &#47; Week 28 (Peds), while maintaining androstenedione control</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#60;0.0001</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">0.0009*</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">*p-value not adjusted for multiplicity</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crinecerfont was generally well tolerated. During the double-blind, placebo-controlled period of the trial, the most common adverse events were headache, fever, vomiting, upper respiratory tract infection, and nasopharyngitis.  There were few serious adverse events, with none assessed as related to crinecerfont. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was a high rate of completion (&#62;95%) in the 28-week double-blind, placebo-controlled treatment period of the trial, similar to the &#62;95% completion rate observed in the double-blind, placebo-controlled portion of the CAHtalyst Adult study.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAHtalyst studies represent the largest interventional clinical trial program conducted in both pediatric and adult CAH patients to date and enrolled a patient population that reflects the unmet need in this condition, with both adult and pediatric patients having inadequate androgen control at baseline despite supraphysiologic glucocorticoid dosing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences, Inc. &#8220;The results from these studies suggest that crinecerfont could represent a new standard of care for CAH patients with the ability to reduce androgen levels through a non-glucocorticoid mechanism. I am particularly excited about our positive results in the pediatric patient population and what improved androgen control in the setting of reduced glucocorticoid doses could mean for important outcomes related to growth and development.&#8221;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data from the CAHtalyst Pediatric and Adult studies, including data from the open-label treatment periods, will support regulatory submissions to the FDA in 2024 and later to the European Medicines Agency. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding the results from both Phase 3 CAHtalyst studies will be provided at the company&#8217;s December 2023 Analyst Day and in a peer-reviewed medical journal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Today at 8&#58;00 a.m. Eastern Time</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will discuss the results, baseline characteristics and additional data from the Phase 3 CAHtalyst Pediatric and CAHtalyst Adult studies on a Conference Call at 8&#58;00 a.m. ET today. Management will be joined by Richard Auchus, M.D., Ph.D., Principal Investigator in the CAHtalyst Adult study and Professor of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan. Participants can access the live conference call by dialing 800-895-3361 (U.S.) or 785-424-1062 (International) using the conference ID&#58; NBIX. The webcast and supplementary materials for the call can also be accessed on the Company&#8217;s website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Classic Congenital Adrenal Hyperplasia</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congenital adrenal hyperplasia (CAH) refers to a group of genetic conditions that result in an enzyme deficiency that alters the production of adrenal hormones which are essential for life. Approximately 95% of CAH cases are caused by a mutation that leads to deficiency of the enzyme 21-hydroxylase (21-OHD). In classic CAH, severe deficiency of this enzyme leads to an inability of the adrenal glands to produce cortisol and, in approximately 75% of cases, aldosterone. If left untreated, classic CAH can result in salt wasting, dehydration, and even death. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently no non-glucocorticoid treatments approved by the U.S. Food and Drug Administration (FDA) for classic CAH. Glucocorticoids (GCs), the current standard of care, are used not only to correct the endogenous cortisol deficiency but typically used at greater than physiologic (supraphysiologic) doses to try to suppress the high levels of corticotropin-releasing factor (CRF) and adrenocorticotropic hormone (ACTH) that result in androgen excess. However, glucocorticoid treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weight gain and diabetes, cardiovascular disease, and osteoporosis. Additionally, long-term treatment with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supraphysiologic </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GC doses may have psychological and cognitive impact such as changes in mood and memory. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as acne, excess hair growth and menstrual irregularities, testicular rest tumors in males, and fertility issues in both sexes. To learn more about CAH, click here. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Crinecerfont</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Crinecerfont is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) antagonist being </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce and control excess adrenal androgens through a steroid-independent mechanism for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD). Antagonism of CRF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receptors in the pituitary has been shown to decrease adrenocorticotropic hormone (ACTH) levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with classic CAH. Our data demonstrates that lowering androgen levels enables lower, more physiologic dosing of glucocorticoids and thus could potentially reduce the complications associated with exposure to greater than normal glucocorticoid doses in patients with classic CAH.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To learn more about crinecerfont, click here.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About the CAHtalyst</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pediatric Phase 3 Study </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAHtalyst&#8482; Phase 3 global registrational study was designed to evaluate the safety, efficacy, and tolerability of crinecerfont in children and adolescents (2&#8211;17 years of age) with classic congenital adrenal hyperplasia (CAH) due to 21-OHD. The study enrolled 103 female and male patients with CAH and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted of a 28-week randomized, double-blind, placebo-controlled period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">followed by 24 weeks of open-label crinecerfont treatment and optional open-label extension. The study started in July 2021, and the open-label treatment portion is still ongoing. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about the CAHtalyst Pediatric Phase 3 study, please visit ClinicalTrialsPediatric.gov.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about the CAHtalyst Phase 3 study in adults (ages 18 years of age and older), please visit Clinical TrialsAdult.gov.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Neurocrine Biosciences, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose&#58; to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington&#8217;s disease, Parkinson&#8217;s disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter, and Facebook.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in collaboration with AbbVie)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEUROCRINE is a registered trademark of Neurocrine Biosciences, Inc. The Neurocrine logo and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the clinical results from, and our future development plans with respect to, crinecerfont, as well as the therapeutic potential and clinical benefits or safety profile of crinecerfont. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements include&#58; top-line data that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of the clinical study&#59; risks that regulatory submissions for our products and&#47;or product candidates may not occur or be submitted in a timely manner&#59; our products and&#47;or product candidates may not obtain regulatory approvals&#59; or that the U.S. Food and Drug Administration or regulatory authorities outside the U.S. may make adverse decisions regarding our products and&#47;or product candidates&#59; our products and&#47;or product candidates will not be found to be safe and&#47;or effective or may not prove to be beneficial to patients&#59; that development activities for our products and&#47;or product candidates may not be completed on time or at all&#59; that clinical development activities may be delayed for regulatory or other reasons, may not be successful or replicate previous and&#47;or interim clinical trial results, or may not be predictive of real-world results or of results in subsequent clinical trials&#59; competitive products and technological changes that may limit demand for our products&#59; uncertainties relating to patent protection and intellectual property rights of third parties&#59; our dependence on third parties for development and manufacturing activities related to our products and our product candidates, and our ability to manage these third parties&#59; our future financial and operating performance&#59; risks and uncertainties associated with the commercialization of our products&#59; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2023. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurocrine Biosciences, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Media&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Linda Seaton</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1-858-617-7292</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;neurocrine.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Tushla</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1-858-617-7143</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ir&#64;neurocrine.com</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># # #</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20231005.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8a23c82e-d2e5-466b-b77d-87fd67dcc786,g:f905e71f-70d7-43cf-b9d1-06aef8084df6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20231005" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20231005">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231005_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20231005_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.neurocrine.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20231005_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8a23c82e-d2e5-466b-b77d-87fd67dcc786,g:f905e71f-70d7-43cf-b9d1-06aef8084df6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_b7e3ccf2-6eca-4a6f-8f83-c57d85e140e6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_93fa9d6b-7ec8-4914-a092-7253874ff663_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a08be730-79de-4579-9e54-84f0b677c009_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f4f8560f-fc9e-4dae-9a51-2d7061c18e28_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_39bd1e9a-c647-466f-b544-dddca578a957_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5f48dcac-c0a3-4e27-b6ce-96cc898629b5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_683a1d96-f0de-4f44-beb3-77918f0babef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_1b225130-32d3-43a8-8fba-c45c4957732b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2e3411ef-8c3a-4234-b4df-ff3f319af952_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9747f905-8bbb-4457-a177-dacd0ce5f3a0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7ccaacca-d693-4a97-8fdb-822faf70a6ff_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_07ed1015-b2e0-474f-8c4f-5c7f0b9eff20_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d32278c7-d62a-4936-9e96-aa886d4b62f3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3b1da495-6fa2-4f1a-9054-303fa8118c8a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_98b80a6a-d0e9-40c0-a577-08556a6a1b27_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8a0c3e8c-b273-428b-88df-6c26fc57470f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9051262b-4e51-4d63-bb14-ea4f01c6e31f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_87eae626-0684-4955-aa65-556094ee2e30_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_297fb9b8-5a65-48b6-a558-0416361030dc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ce5f81d6-d10e-4703-9e98-d90529985225_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_6a6bef0e-237f-4776-86df-3235e445b8c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_559bdb32-9fe4-4fa3-82c1-dbd66582c7d4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20231005_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8a23c82e-d2e5-466b-b77d-87fd67dcc786,g:f905e71f-70d7-43cf-b9d1-06aef8084df6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/Cover" xlink:type="simple" xlink:href="nbix-20231005.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3e91aa77-d007-4370-a848-3d90d322129a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_DocumentType_3e91aa77-d007-4370-a848-3d90d322129a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_322b0922-4102-4d2a-94b1-365e2d9d1a22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_DocumentPeriodEndDate_322b0922-4102-4d2a-94b1-365e2d9d1a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f7ee4afd-0095-4518-ae6b-5fe46ed6f5dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityRegistrantName_f7ee4afd-0095-4518-ae6b-5fe46ed6f5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bdb23c96-9dea-495c-aaac-3a2fb0f3d6b6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bdb23c96-9dea-495c-aaac-3a2fb0f3d6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e03aeb30-e0cb-4dc9-b612-a03e122777c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityFileNumber_e03aeb30-e0cb-4dc9-b612-a03e122777c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_704bc544-64cd-4d0e-8011-a261c98c2537" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityAddressAddressLine1_704bc544-64cd-4d0e-8011-a261c98c2537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d51504b5-b407-4db5-b051-3d9736fc2027" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityAddressCityOrTown_d51504b5-b407-4db5-b051-3d9736fc2027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ac8dcf15-fa7f-40f8-a326-b12c8decb140" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityAddressStateOrProvince_ac8dcf15-fa7f-40f8-a326-b12c8decb140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0dec781a-ce04-44ae-b9dd-430a64da0a82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityAddressPostalZipCode_0dec781a-ce04-44ae-b9dd-430a64da0a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c64623ea-378a-4674-886f-ae4a1f1393cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_CityAreaCode_c64623ea-378a-4674-886f-ae4a1f1393cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4299f1fa-9052-4f35-ba6c-e3aca84bef00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_LocalPhoneNumber_4299f1fa-9052-4f35-ba6c-e3aca84bef00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_34a749ff-2e4a-4553-8479-c2e3f0213018" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_Security12bTitle_34a749ff-2e4a-4553-8479-c2e3f0213018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_58f968a9-8d71-4385-8f5a-acf8b5f03d2d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_TradingSymbol_58f968a9-8d71-4385-8f5a-acf8b5f03d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_02fef346-42aa-4434-89a7-29100b42da41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_SecurityExchangeName_02fef346-42aa-4434-89a7-29100b42da41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_519e0eec-e156-492b-8458-28a68b3537d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_WrittenCommunications_519e0eec-e156-492b-8458-28a68b3537d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_cde3f65b-54c7-44d0-9c68-7ae1636759b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_SolicitingMaterial_cde3f65b-54c7-44d0-9c68-7ae1636759b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_fd6f3d0b-9856-49fe-b1a2-71341c585282" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_PreCommencementTenderOffer_fd6f3d0b-9856-49fe-b1a2-71341c585282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_51289303-e949-49dc-909e-cd4c4015e79f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_51289303-e949-49dc-909e-cd4c4015e79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6aafeed6-7382-49fc-bf05-7d09d17d311f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityEmergingGrowthCompany_6aafeed6-7382-49fc-bf05-7d09d17d311f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_62a07458-cd41-410d-b800-9f21e8aeba87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_AmendmentFlag_62a07458-cd41-410d-b800-9f21e8aeba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_27b24f85-e294-4b95-a8a7-430da1eb4046" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityCentralIndexKey_27b24f85-e294-4b95-a8a7-430da1eb4046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f2d680e5-d1ac-4102-8273-fbf7d4a8d36f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_eb6b7267-518c-4842-95be-bdc67fcb56f3" xlink:to="loc_dei_EntityTaxIdentificationNumber_f2d680e5-d1ac-4102-8273-fbf7d4a8d36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>nbix-20231005_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nbix-20231005_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MR:G++?KO,[ZZ=-["QGBEC:/'2X35&/LW**Y[OF]ZFI[;;NWH?=GBS]I;X>^
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M0+.< Y>UE3?-Z+\[GXK+PHXSIT7EN'QT?J[TM[2HE9[KEY7OU2=F?G)^Q?\
ML:^(/VOOB'#9VD-Q9^%;.53K&KE,101CEHHVZ-,PX"C.W.XX Y_2;_@HSX?L
M_"?_  3U\9:7IUO':Z?INGV5K;0H/EBC2ZMU51[  "O>/#?AG3?!VB6^FZ3I
M]GI>GVJ[(;:TA6&&(>BJH 'X5E_%GX5:)\;OA[J7A?Q%:R7FBZLJ)<PI,\+.
M%=9%PRD,/F53P>U>7B<XE7Q,*DE:,6G;YZ_,_1,@\+Z639#C,!AYJ>(Q%.47
M-Z*[BU%+=J*;UW;W[)?C7^QA_P G<?#/_L8[/_T8*^YO^"O_ .S!_P )Q\/+
M7XD:3;[M5\*IY&J!%^:>P9L[SZF)SN_W7<]J]6\"_P#!-#X/_#?QII7B#2/#
MMY;ZIHMTEY:2MJMS((Y4.5)5G(.#V(Q7N6JZ5;Z[I=S8WD,=S9WD303PR+N2
M6-@592.X()!'O75C,\C+%4\10O[NCOU[K=]#YWA/PCQ&'X<QN1YQ*#=>2E%P
M;?*U%<LM8QU4ELMU=7U/Q[_81_:<D_9<^/-CJEQ*X\.ZN%L-:C'00LWRS8_O
M1,=WKMWCO7ZP_&:YCO/@=XLFAD26&70KQT=&W*ZFW<@@]P?6O'E_X)2?!%1Q
MX8OMOI_:]W@?^1*]H\/?"K1_#/PMB\&VT=TV@PV+::D4US)+(+<J4V>8Q+\*
M=H.<@ >E9YOF&%Q-6%>BFI+>Z6J^_<]3PRX+XBR#+L1E.93IRI23=/EE)N,F
MK23O!>Z]'IL[Z/F/P[TS[UK_ +T?\Q7Z6?\ !8[_ )-9T'_L8K;_ -)[BNSB
M_P""5OP4A*;?#5]^[((_XF]UQCI_RTKU7XX?L^^%OVBO"-OH?BRQFO\ 3;6Y
M6\CCCN9(")%5E!W(0>CMQG'->ACL^P];$T:T4[0;;T76VVOD?&\(^#N>97D.
M:Y9B)TG/%0A&#4I-)QYK\S<$U\2M9,_-3_@E7_R>OX?_ .O"^_\ 1!K]-/C=
M\'M(^/?POU;PKKD>^QU6$IYBC]Y;2#E)4]&1@&'TQT)KB/@_^P9\,O@3X\MO
M$OAG1;JRUBTCDBBE?49YE577:WRNY'(]J]BKRLXS.&)Q4<10NK);[W3;\S]"
M\+^ L3D7#]7)LXY*GM)S;46Y1<91C&SO&.]G?38_#OXO_"C6/@=\2M6\*ZY%
MY>HZ/,8F8#"7"'E)4_V'4AA]<=0:^H/^"+G_ "7WQ9_V+X_]*8Z^U/CK^QM\
M/?VD->LM4\6:&U]J%A ;:*>&ZEMW,9.[:QC8;@"21G.-Q]:;\"?V-?A_^S=X
MCO-6\(Z3<:??:A;?9)GDOIK@-'N#XP[$#D#D<UZ^,XCHXC!.C)/G:\K7^_\
M0_-N&_ W,\EXKI9G0JPEA:<W)7E+VG*TTDURVNKVOS:VOI>Q^;O_  4L_P"3
MVO&W^]:?^DD-7OV9O^"B_BK]ESX9_P#"+Z/H/A_4;/[7+>>=>&;S=TF,CY6
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MU+6MTNN37EI(XZ+-$YRRD\'!Z=CTKZ]M[>.TMXXHD6..-0B(HPJ@<  >@I]
M'S-^P!^UOXJ^*^K^*OAK\4-/33?BA\/91%?2PQ%+;6;<G"W4? 7NN0O!#HP
M#%5YK]EC6KV[_P""JW[1=G-?7LUG:V&D&&WDN':& F%<[$)VKGO@#-?7V.:^
M./V4/^4LW[27_8/T?_T0M '#?%7X$:9^U'_P5X\6>$?$FK>*K71+/P3::E%#
MI.LS6.V97C3/R'&"LC9&.3@]J]8M?^"/_P +K2ZAF77/BANAD61<^+[L@E2"
M,C/(XZ5Y#\3?B+XP^&/_  6,\7:AX)\!W'Q#U:3P+:02:;%J46GM#"9(B9O,
MD!4@,%7;U._VKWKX=_M1_&[Q1X^T?3=:_9UU#P[H]]=I#>ZH_BNSN%T^(GYI
M3&J[GV_W1R: /'/^"R(\8ZC\5/@'I?@76+S2/$VI:M?KIS0W;6\<ERBVSQ!\
M':PW#&&!'S8/!-?2/[$O[5-G^UO\#K/Q!]G_ +-\0Z?(VF^(=*<%9-+U"+B6
M,J>0I/S+G^%@.H./%O\ @HS_ ,GI?LG_ /8UW?\ *VJM^T[IUQ_P3[_:GMOC
MIHL$Q^'/CJ:+2OB+8P+E;.9CM@U15'<$X<XY)/>3@ O?\%>=:OM&TGX*FROK
MZQ,_Q&TZ*4VUP\/FH=V5;:1N4^AXKW;]KK]IS1_V1/@1K'C;6(VNA8A8;*R1
MMLFH73\10J>V3R3@X56.#C%?//\ P5YU*WUGPM\![RSFBNK6Z^(NES0S1,&C
ME1@Q5E(X(((((Z@U)_P52@3Q+\=OV8O#NH?-H6K>.UDO(F_U<K1F 1AOKYCC
M\30!!\/?V$_'G[86BP>,/V@O'7BNUDUA1=6G@KP_?-INGZ-$V"D<NWYGDVXW
M9Y!X+,>E_P 6?\$H#\,M/DU?X(?$CQYX#\568\RWAN]8DOM,O6'(CFCDS\K'
MC)W ?W3TK[&HH ^>_P#@GU^U]JW[3/@O6M'\9:.WA_XD> [S^R_$-EY1CBE<
M%E6>('^%BC@@$@,IP=I7/S3^S9^R-X?_ &POVG?VBI/%VM^.$_X1KQM-;6,>
MF^(+BSCCCD>9B-JMC@J,>@K]&L<U^<'[+7QF^(GPI_:B_:2C\"_"FZ^)$-]X
MYF>\EAUN#3OL#*\P52)0=^X$G(Z8H ^DOA7_ ,$O_AW\(/B-H_BC2]7^(<^H
MZ'<?:;>.]\3W-S;NVTKAXV.UQACP?:O+OB.?$G_!0+]N?QI\+&\6Z]X/^&/P
MOL[;^U;;1+@VMYK]U.H;:\HY$8^88Y'R=,ME?;O@%^T'\6/B3\0ETSQC\$;[
MP#HIMI)CJTOB*UOE$B[=L7EQ@-\V3ST&WWKSS]HC]CGXD>#/VE[SXT_ S6M%
MM_$FLVD=IX@\.ZT&6QUM8PJJRNOW7VJHYVX*Y##+ @',_%__ ()4_P#"H/!M
MYXH^ WB[QYX8\>Z+$;JTM7UR2ZM=8*#)@D24D9?&!N.S) 88.1]1?LX>+_%7
MCOX'^&]4\;Z#)X9\77%H!JNG.5/D3J2C$;2PVOMW@9. X'45\Z_\//?$GP.O
M+:U^.WP=\5?#^UDD6!M?TUUU;1]Y. 2\?*CV!=O8U]8^%?%6F^./#5CK&CWU
MMJ6EZI ES:75NX>*XB<95U(Z@@T :%%%% !1110 4444 %%%% !1110 4444
M %%%% !7R/\ \% _^"6.B_M6W,_BOPO/:^&_'P0"61T/V/60HPJSA1E9 .!*
MH)P &# #;]<45M0KSHSYZ;LSULESO&Y5BHXS SY9K[FNS6S3[/UW/P ^-G[-
M'C[]G36)+/QGX5U;1=K%4NFB,EG/CNDZYC8?CGU K@ENHW&5DC(]0PK^CB[L
MX=0MGAN(HYH9!M>.10RL/0@\&N$U[]F?X:W:S7MQ\// ]S<1JTF^70[9F8@9
MY.S->]3X@TM.&ODS]RR_QU7LU'&X3WN\)63^33:_\"9^#7@7P-KGQ0UV/2_#
M.CZIX@U&8[4MM.MGN)#]0H.T>YP!7W%^SQ_P3I\-?LI>'(_BI^T;J6FZ?::8
M1/IWAD2+.9YQR@F"Y\Z3."((\KGEB0"!VGQV_P""B'BKX1:M>>%?A_X<\%>$
MHHR5%Q'IIE*8[K&K(F?]X,/:O,_AS^Q%XL_;_P#& USQM\6=2NKQ@=K3:5YW
MD*>2D2^>J1K[*@'L:[*N(J3A>H_9P\M6_N6AZF:<98[,,-S5I+!X=_$TW.K)
M=DXQM&_>S:/#?VW_ -L_6OVS/BI_;%Y')IOA_2PT&BZ47R+.(D;I'QP9GP"Q
M'  "C@9.U^Q3_P $Z_&?[8VLV]ZL5QX>\#QN/M6N7$6//4'E+53_ *USTW?<
M7N2?E/Z#? ?_ (([?"'X/7D%_JMG?>.M4A(99-;=6M48'.1;H!&?^!AZ^J+2
MTBL+6.""*.&&%0D<<:A5C4#   X  XP*XJ^<PIT_981?/_)?YGQ^8>)6!R_"
M+ \.TK65E.2LEYQCJV^MY6UW3.9^"OP6\.?L^_#?3?"GA73X]-T?3$VH@^:2
M9SRTLC=7D8\LQZGVP*ZJBBOGI2<G=[GXQ6K5*U256JW*4G=MZMM[ML*^??\
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M*/C9_P $]O@_^T5X]F\3^,O!\.M:Y<0QV\ERU]<Q%DC!"#;'(J\ GM7*V_\
MP2*_9XM+F.:/X=6JR0NLB'^T[WAE((/^N]10!Q7_  49_P"3TOV3_P#L:[O^
M5M7UAX^\":3\4/!.J^'==LH=0T?6K62SO+:4966-P01['G((Y! (Y%8OQ%^
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MY('-4?CO^PK\)?VEM3&H>,_ ^CZKJB@+]O0-;79 Z9EB*NV.VXG%<_\ "O\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139967297753136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  05,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>nbix-20231005_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20231005.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2023-10-05</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-10-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">12780 El Camino Real,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">617-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!^#^1BGSUK!;UNH?A^F_4$L#!!0    ( %(X15>?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( %(X15<'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 4CA%5R7@=HGN    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 4CA%5YE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !2.$57B"2-24<$  !]$   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 4CA%5Y^@&_"Q @  X@P   T              ( !B@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !2.$57EXJ[',     3 @  "P
M@ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " !2.$57JL0B%C,!   B @
M#P              @ %/$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M4CA%5R0>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 4CA%5V60>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-20231005.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="nbix-20231005.htm">nbix-20231005.htm</File>
    <File>nbix-20231005.xsd</File>
    <File>nbix-20231005_lab.xml</File>
    <File>nbix-20231005_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nbix-20231005_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nbix-20231005.htm": {
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20231005",
   "dts": {
    "inline": {
     "local": [
      "nbix-20231005.htm"
     ]
    },
    "schema": {
     "local": [
      "nbix-20231005.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20231005_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20231005_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.neurocrine.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231005.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nbix-20231005.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurocrine.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000914475-23-000065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-23-000065-xbrl.zip
M4$L#!!0    ( %(X15?&WFE+A0T  /!8   1    ;F)I>"TR,#(S,3 P-2YH
M=&WE'-MRXCCV?;Y"Z][M2:IBXPMW$J;2A.YANYND(%W3M2]3PI)!&V-[9)'
M?OT>R3:78!*23AK(Y"78DHYT[A=)/OUM.O;1+>4Q"X,SS3),#?W6//V'KG__
MT/N"+D)W,J:!0"U.L: $W3$Q0F)$T1\AOV&W&%WY6'@A'^NZ&M4*HQEGPY%
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M%%81X=2CG +]XQSZ2S&KQXI/L RDQ*XN@.IG6LS&D2^9IMZ-N%SE"JF-:4P
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MME9,'('@*MT%P0U"E7]-8JIZ <W3DJ6\'\=43I9<\Y&D57/Y,SFYNFXI&1<
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MA[Q!I*2D37D\[Q#6J[1>.)2O7Z]@O%_[[T<[Z 3[Q5Y._@!02P,$%     @
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MB<:MN?V0BDK_S,SW/N;'10&1#K_O\VCT7VJ)[@*BC603'3E'BI&-:(&U3.R
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M.Z)K='\C3!L-(C'$+B.2@1ROX'3;(5QQ7K*GQ9"5G!UQSNL2?'U!'.EY,7J
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M,;:PW9)-[A 33R:F,!DR@!FZ &0XGA]FY?VH';_Q+D3BL7^=>4.J"3(LC#D
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MO L;$M0D?E**E2:XK3C8Z<QVFVY_E;<93MI6W;@+3 J[7T'O7>"7D2JOH<U
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M]>I?RE8IR=*])=BVBA]Q4IM%8F)!#;ANCPDI\PS;\@'3(*^=N=#:CO]!@G_
M!S1:)>#3PO"MK=TMR4V2!%3V;ZLB 32A+H/RY!@_$7"5O74TWH>)3?-]Z?V
MVY]J.2E#5(\%+P09U*LFII-X]6Z7?^L5AG&.<614O.>X-2D=KM#.<0PF7(]&
M145C-E>7V@ZC89?&I4_) *![JWS=9%&68;K1*X-'#1F%K_J>),C9;[(ZO\T8
M+@/BA+GV=HQ!3/O&4V8M9,#JQ [H$M+Y,(J"6.K*C,O&M"]:^4(K:X/+O\KX
MR6^JV5J)#&Q^Y.QY0;V9C).B):3GSR!( QK%QX\/0,O?\JO<8C3O$6Z,-&LM
M!RY@J%?R2H$Q)\+ D.V"]E2J@W;SMPL%)CT!CNT8\#+M.YCRCB-?,T;W?6-1
M[[M X8GJ+/?UY+TL@\1?@ 1J)^JH/FS%P!MU9:PAL95 CS>#/+X2;5[]%^KP
M\JN 76=.PM=%O'$]_Z.WP*L[W/QW!.0^%=]X!:\&[2>B=[%@=-@?!&J8W;VV
MG(&=Z9V"=-T4(HE-7&N^*T^A(^'H_D8520W6#J2#NVN \08]@K2C@4S6"0(/
M!+!97MN-UMDVE:01I31T!(F^"*V]'!3S95)1%K#M53I7NX4(I!<9%XW!2KJZ
M,>@]!PA-OE''D^CKT%G=@I*8X>163<B98:X.AJM;PLE0RB!?\W5V86^RB#W_
M-7MIZ#5F(<NVA;=->%78XC&D%)N(>XNN0SFT1B\/<T!\3*2^=&\TF^QFBFG:
M?Q_]J) Q/6W6!Z,=F+YP;5Y:/=N+1R]AO];4)??"V$9/SZ7'RUM^O_W:6"?@
MFZ9KT3:LLI" _<PB04DO!,$*K4P)H!,+]];BK>8Q'R7C:S;$-)TQZK*L(*LR
MO52,KOR2T$H\59MCPPU^,"^I>_$&[I!2;:7HNLY/IKHUF,G$S],.T]6'U7,>
MG)BH)#&G_R4C!=SZ]WY28B?X=Q/:O1/@U_P37^"OP'\6V^O^'_!%G_;EHVZW
MOK^XFOYK8]C'YSL$8=F4 CUKW2@#YH_8I_X*#:!\9O#,/A7QO>0^#?BQX=46
M&NZ'J[BTFEN$PK2P[\!U?[V%R5R>",,?7?C#^TSX!^ GA2XUGQ9XKT71[.W0
MOB2Y5IIO]F.,$O(Q[!036;\>?V-OA?\ M-M')XX\%Z-KUU NV.[>,PW48[ 3
M1E9,#L-V/:N&^'__  2J^ ?PWUV'4['X=Z9>7UNP>*34YYM06,CIA)G9/S%
M&9^P/\?/B=^U5K_BSQYKUE#X?^%M]+Y'@[3)K$1WUU$",W4DF22I XP,%G;!
M(4$\A^RA_P I9OVDO^P?H_\ Z(6OL6&%+>%8XU6..,!551A5 Z "N0\*? +P
MEX(^+'B3QQI>DK:^*/%T<,6K7HGD8W:Q*%C!1F*+@ #Y0,]\T ?,'A/4;?3/
M^"WWC:2YN(;>/_A7=L TL@12?.@XR>]?7X\8:23_ ,A33N>/^/E/\:\H^-G_
M  3V^#_[17CV;Q/XR\'PZUKEQ#';R7+7US$62,$(-L<BKP">U<K;_P#!(K]G
MBTN8YH_AU:K)"ZR(?[3O>&4@@_Z[U% '%?\ !1G_ )/2_9/_ .QKN_Y6U?6'
MC[P)I/Q0\$ZKX=UVRAU#1]:M9+.\MI1E98W!!'L><@CD$ CD5B_$7X!>$OBQ
MXT\)^(?$&DKJ&L>![I[W1+@SR1_8IGV[F"JP5L[%X8$<5V- 'Y$_M 77B7X
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MBXX!Y6G'3WU%G1GV!*295)E9O3:$4)M]ETK<&9>/'Q[$C?GTU&?SB<X#3_-
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M*5X7&J2?\7C_I6;BK8I,%M,G+[(X-QIC+Q'Z(4Q8%L_Z$Y;-0&*]@'9//H&
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M1N<YE.$=-FZIL,"]_M>D\\G>P.7*9<:H+%+:J<MY< 34<L.1UY9N3.A0(7X
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MCK^F99H\_S=02P$"% ,4    " !2.$57QMYI2X4-  #P6   $0
M    @ $     ;F)I>"TR,#(S,3 P-2YH=&U02P$"% ,4    " !2.$57&*R_
MR6P"  !V!P  $0              @ &T#0  ;F)I>"TR,#(S,3 P-2YX<V10
M2P$"% ,4    " !2.$576&SYHSY&  #21P  %               @ %/$
M;F)I>"TR,#(S,3 P-5]G,2YJ<&=02P$"% ,4    " !2.$57OD5]A4P*   :
M70  %0              @ &_5@  ;F)I>"TR,#(S,3 P-5]L86(N>&UL4$L!
M A0#%     @ 4CA%5TGUH#&E!@  XC   !4              ( !/F$  &YB
M:7@M,C R,S$P,#5?<')E+GAM;%!+ 0(4 Q0    ( %(X15<4S9<O=!D   J#
M   :              "  19H  !N8FEX,C R,S$P-2UE>&AI8FET.3DQ+FAT
7;5!+!08     !@ & (X!  #"@0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
